Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

818
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLS1 inhibitor CB-839 inhibits the malignant progression of 5-FU resistant hepatoma cells by regulating glutamine metabolism.

Chemico-biological interactions·2025
Same author

Real-time and label-free monitoring of monoclonal antibody secretion rates using a PC-TIR biosensor.

Biosensors & bioelectronics·2025
Same author

Barriers and facilitators to implementation of proper limb positioning in hemiplegic stroke patients: a qualitative study.

Revista da Escola de Enfermagem da U S P·2025
Same author

CYP2A6 suppresses hepatocellular carcinoma via inhibiting SRC/Wnt/β-Catenin pathway.

Acta pharmacologica Sinica·2025
Same author

High level of initial Aspergillus fumigatus-specific IgE links increased risk of exacerbation in allergic bronchopulmonary aspergillosis patients.

Respiratory research·2025
Same author

Inhalable Mucociliary-On-Chip System Revealing Pulmonary Clearance Dynamics in Nanodrug Delivery.

ACS nano·2025

Related Experiment Video

Updated: Nov 11, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.3K

Targeting galectins in T cell-based immunotherapy within tumor microenvironment.

Qiu-Yang Jin1, Ying-Shuang Li1, Xing-Hui Qiao1

  • 1Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China.

Life Sciences
|March 31, 2021
PubMed
Summary

Tumor immunotherapy shows promise but needs support. Targeting galectins, which regulate immune responses in the tumor microenvironment, combined with immunotherapy, may offer a novel treatment strategy.

Keywords:
GalectinImmune checkpoint therapyT cellTumor immunotherapyTumor microenvironment

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Related Experiment Videos

Last Updated: Nov 11, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Tumor immunotherapy is a rapidly advancing field with significant advantages over traditional therapies.
  • Despite its potential, immunotherapy faces challenges in clinical application due to its complexity.
  • Galectins play a crucial role in modulating the tumor microenvironment and immune system responses.

Purpose of the Study:

  • To review the expression and immune functions of galectins within the tumor microenvironment.
  • To explore the potential of targeting galectins in combination with immunotherapy for cancer treatment.
  • To discuss the value of combining anti-galectin therapies with checkpoint inhibitors.

Main Methods:

  • Literature review of galectin expression and function in cancer.
  • Analysis of galectin's role in immune regulation within the tumor microenvironment.
  • Evaluation of preclinical and clinical data on galectin-targeted therapies and immunotherapy.

Main Results:

  • Galectins are frequently expressed in tumors and influence both innate and adaptive immunity.
  • Galectins contribute to immune suppression within the tumor microenvironment.
  • Targeting galectins may overcome resistance to current immunotherapies.

Conclusions:

  • Galectins are key regulators of the tumor immune microenvironment.
  • Combination therapy targeting galectins and utilizing checkpoint inhibitors presents a promising strategy for enhancing tumor immunotherapy.
  • Further research into anti-galectin therapies is warranted to optimize cancer treatment outcomes.